Connect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China

Stock Information for Connect Biopharma Holdings Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Connect Biopharma Holdings Limited

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.